Overview

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (pancreatic and prostate) expressing high levels of prostate stem cell antigen (PSCA). Participants' T cells are modified to recognize and target the PSCA tumor marker on cancer cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bellicum Pharmaceuticals